BioSpace News Archive

Daré Bioscience, Inc., a leader in women’s health innovation, announced that the company’s President and CEO, Sabrina Martucci Johnson, and Medical Advisor Andrew T. Goldstein, MD, will participate in the following conferences in November 2023.

Portage Biotech Inc. today announced the presentations of updates from its ongoing IMPORT-201 Phase 1/2 trial of PORT-2 (IMM60), an invariant natural killer T cell (iNKT) engager for patients with NSCLC and advanced melanoma, and its ADPORT-601 adaptive Phase 1a/1b trial for PORT-6 (A2A inhibitor) and PORT-7 (A2B inhibitor) in multiple solid tumors at SITC.

Oryzon Genomics, S.A. announced today that its management will give an update on corporate progress at several international events in November.

OrthoPediatrics Corp. announced the Company has entered into an exclusive Distribution Agreement with Ora Medical, based in Montreal, to sell Ora Medical’s gait trainer, The Levity, a device designed for children with walking difficulties.

Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AL102, a Gamma Secretase Inhibitor (GSI), for the treatment of desmoid tumors (DT).

Anavex Life Sciences Corp. announced the appointment of David Goldberger, RPh, MLS as Senior Vice President Regulatory Affairs.

eFFECTOR Therapeutics, Inc. today announced that the Company will participate in a fireside chat discussion and host 1x1 meetings at the 2023 Stifel Healthcare Conference taking place November 14-15, 2023 in New York, NY.

Adverum Biotechnologies, Inc. today announced the appointment of C. David Nicholson, Ph.D., as an independent member of its Board of Directors, effective November 3, 2023.

Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, presented final data from a 24-month, Phase 2 study of Tinlarebant in adolescent STGD1 (“LBS-008-CT02”) at the American Association of Ophthalmology (AAO) Annual Meeting.

Aethlon Medical, Inc. today announced that it will issue financial results for its second quarter ended September 30, 2023, at 4:15 p.m. ET on Tuesday, November 14, 2023.